Revenue generated by Breathe Life Sciences (BLS) slipped to A$1.7 million in Q3 FY24 with parent […]
Q3 and Q1 FY24 Financial Roundup: Bioxyne, Melodiol Global Health, Emyria, Zelira, Elixinol, Wellnex Life, and Argent BioPharma
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
Argent BioPharma
Bioxyne
Breathe Life Sciences
Elixinol Wellness
Emyria
Health House International
HOPE 1
Melodiol Global Health
Sam Watson
Wellnex Life
Zelira Therapeutics
Related Articles
